Stifel Nicolaus initiates Sarepta Therapeutics with a Buy

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Sarepta Therapeutics (SRPT +1.2%) moves up today after Stifel Nicolaus initiated the shares late yesterday with a Buy and a $51 price target.

Stifel says the company represents an attractive investment biotechnology opportunity in the rare orphan disease space.

Its thesis is predicated on the clinical and commercial success of Eteplirsen, its lead pipeline asset, which has already demonstrated compelling safety and tolerability in a Phase 2b clinical study.

In addition, SRPT's broad platform technology gives them a leg-up for potentially discovering additional clinical candidates for genetically inherited and difficult to treat infectious diseases.